What is Entrada Therapeutics, Inc. (TRDA)?

Entrada Therapeutics, Inc. (TRDA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of TRDA?

The current price of TRDA is $4.54. Prices are updated in real time on Stocks360.

What is TRDA's price-to-earnings (PE) ratio?

TRDA's trailing twelve-month PE ratio is -1.14, based on current price and earnings per share data available on Stocks360.

What is TRDA's market capitalization?

TRDA's market capitalization is $176,577,794.00, placing it in the small-cap tier.

Entrada Therapeutics, Inc. (TRDA)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.54

Market Cap

$176.58M

PE (TTM)

-1.14

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.24

Day Range

$4.26 – $4.55

52-wk Range

$4.11 – $16.45

Avg Volume

N/A

Volume

317.34K

Entrada Therapeutics, Inc. (TRDA) is a publicly traded company in the Healthcare sector. Latest price: $4.54. Market cap $176.58M. Trailing PE -1.14. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $6.95 2026-10-30 · $4.54 (-34.68%)

Earnings

Most Recent

Aug 5, 2026

EPS $-1.01 vs est. $-1.05

Beat by $0.04

Next Earnings

Nov 5, 2026

EPS estimate $-0.98

Proprietary Signals

Signal snapshot temporarily unavailable.

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.14×
P/S (TTM)	37.68×
P/B	0.82×
PEG	0.02×
P/FCF (TTM)	-1.31×
EV / EBITDA	-0.76×
EV / Sales	26.85×
Earnings Yield	-86.58%
Free Cash Flow Yield	-76.09%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$125.84M
Revenue (TTM)	$4.69M
Net Income (TTM)	-$152.88M
Free Cash Flow (TTM)	-$134.35M
Net Debt	-$50.74M
Working Capital	$211.33M
Gross Margin	-754.72%
Operating Margin	-3767.07%
Net Margin	-3537.73%
Return on Equity	-57.61%
Return on Invested Capital	-62.61%